 

Active ingredient: Atenolol and Chlorthalidone 

 

Form/Route: Tablet/Oral 

 

Recommended studies: 2 study 

 

1. Type of study: Fasting 


Design: Single-dose, two-way crossover in vivo 

Strength: 100 mg/25 mg (100 mg/25 mg dose) 

Subjects: Healthy males and nonpregnant females, general population 

 

 

2. Type of study: Fed 


Design: Single-dose, two-way crossover in vivo 

Strength: 100 mg/25 mg (100 mg/25 mg dose) 

Subjects: Healthy males and nonpregnant females, general population 

Additional Comments: Please refer to the Amantadine Hydrochloride Tablet Draft 
Guidance for additional information regarding fed studies. 

 

 

Analytes to measure (in appropriate biological fluid): Atenolol in plasma and Chlorthalidone 
in whole blood. 

 

Please refer to the Amiodarone Hydrochloride Tablet Draft Guidance for additional information 
regarding long half-life drugs. 

 

Bioequivalence based on (90% CI): Atenolol and Chlorthalidone 

 

Waiver request of in vivo testing: 50 mg/25 mg based on (i) acceptable bioequivalence studies 
on the 100 mg/25 mg strength, (ii) acceptable in vitro dissolution testing of all strengths, and (iii) 
proportional similarity of the formulations across all strengths. Please refer to the Mirtazapine 
Tablet Draft Guidance for additional information regarding waivers of in vivo testing. 

 

Dissolution test method and sampling times: 

Please note that a Dissolution Methods Database is available to the public at the OGD website 
at http://www.accessdata.fda.gov/scripts/cder/dissolution/. Please find the dissolution 
information for this product at this website. Please conduct comparative dissolution testing on 12 
dosage units each of all strengths of the test and reference products. Specifications will be 
determined upon review of the application. 


